Gilead Sciences, Inc. (GILD)
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
Scored against other Healthcare stocks, not a fixed scale.
The quick read
Gilead Sciences is right in the middle: the good and the not-so-good roughly cancel out.
- What's working
- The stock has been climbing and sits near the top of its range for the year.
- Worth watching
- Its price is high compared with other healthcare companies, given its sales and profits.
Analyst price target
~12-month · 26 analystsPublished targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
About Gilead Sciences, Inc.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients…
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 17,000
- Headquarters
- Foster City, CA
Similar stocks
What’s behind the score
Valuation
P/B 16.4 — lower than 11% of Healthcare peers
P/S 6.4 — lower than 30% of Healthcare peers
EV/EBITDA 14.7 — lower than 47% of Healthcare peers
EV/Revenue 7.1 — lower than 30% of Healthcare peers
PEG 2.3 — lower than 19% of Healthcare peers
FCF yield 5.0% — higher than 76% of Healthcare peers
Profitability & quality
Gross margin 79.6% — higher than 97% of Healthcare peers
Operating margin 33.7% — higher than 80% of Healthcare peers
Net margin -10.6% — higher than 7% of Healthcare peers
ROE -20.7% — higher than 7% of Healthcare peers
ROA 14.1% — higher than 93% of Healthcare peers
Financial health
Debt/equity 2.2 — lower than 4% of Healthcare peers
Current ratio 1.26 — higher than 31% of Healthcare peers
Quick ratio 0.90 — higher than 48% of Healthcare peers
Cash/debt 0.19 — higher than 52% of Healthcare peers
Debt/EBITDA 1.80 — lower than 69% of Healthcare peers
Growth
Revenue growth 10.2% YoY — higher than 67% of Healthcare peers
Ownership & investor activity
Payout ratio 43.5% — typical for Healthcare peers
Net insider selling, -3.7% of insider shares
Institutions net sold, -11.1% of shares held
Insiders hold 0.1% of shares outstanding
1.8% of float sold short
Momentum
Above its 50- & 200-day averages
91% of the way from its 52-week low to high